This collection of articles and expert perspectives explores the critical challenges shaping ADC development today, from analytical strategy and impurity control to linker technology innovations and evolving regulatory standards. It also examines the collaborative expertise needed to bring these transformative therapies to patients. The post Analytical Challenges for Antibody-Drug Conjugate (ADC) Manufacturing appeared first on GEN – Genetic Engineering and…
You may also like
EC approves Erbitux combination for first‑line...
FDA approves Leqembi Iqlik subcutaneous initiation...
AstraZeneca agrees on $1.5bn deal with Dizal...
Cherry appoints Peter Henshaw as new Managing Director
Novel Epigenetic Therapy Targets Treatment-Resistant...
FDA Issues Proposal to Streamline Registration for...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.